Patents by Inventor Maribel Beaumont
Maribel Beaumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043491Abstract: Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.Type: ApplicationFiled: December 21, 2021Publication date: February 8, 2024Applicant: MERCK SHARP & DOHME LLCInventors: Stephen E. ALVES, Glareh AZADI, Maribel BEAUMONT, Lia BENSO, Alan C. CHENG, Peter GEORGIEV, Brian E. HALL, Veronica M. JUAN, Renee MOORE, Venkataraman SRIRAMAN, Jie ZHANG-HOOVER
-
Patent number: 11649290Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: November 27, 2019Date of Patent: May 16, 2023Assignee: Merck Sharp & Dohme LLCInventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
-
Publication number: 20220041727Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: October 8, 2021Publication date: February 10, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 11168135Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: May 17, 2019Date of Patent: November 9, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 11168136Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: May 17, 2019Date of Patent: November 9, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 11155619Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: May 17, 2019Date of Patent: October 26, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Publication number: 20200157220Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: November 27, 2019Publication date: May 21, 2020Applicant: MERCK SHARP & DOHME CORP.Inventors: JUHA PUNNONEN, MARIBEL BEAUMONT, MARIE-ANGE BUYSE, CARLO BOUTTON, BRUNO DOMBRECHT, BJORN VICTOR
-
Patent number: 10544222Abstract: The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: November 17, 2016Date of Patent: January 28, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Juha Punnonen, Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, David Vlerick, Robert A. Kastelein
-
Patent number: 10501542Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: November 17, 2016Date of Patent: December 10, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
-
Publication number: 20190330339Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: May 17, 2019Publication date: October 31, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Publication number: 20190330340Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: May 17, 2019Publication date: October 31, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Patent number: 10323090Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: November 17, 2016Date of Patent: June 18, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, David Vlerick, Robert A. Kastelein
-
Patent number: 9732151Abstract: The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.Type: GrantFiled: October 31, 2012Date of Patent: August 15, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Maribel Beaumont, Jeanine D. Mattson, Jennifer R. Louten, Terrill K. McClanahan, Rene de Waal Malefyt
-
Publication number: 20170137520Abstract: The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: November 17, 2016Publication date: May 18, 2017Inventors: Juha Punnonen, Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, David Vlerick
-
Publication number: 20170137521Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: November 17, 2016Publication date: May 18, 2017Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor
-
Publication number: 20170137517Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: ApplicationFiled: November 17, 2016Publication date: May 18, 2017Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, David Vlerick
-
Publication number: 20150368344Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.Type: ApplicationFiled: June 19, 2015Publication date: December 24, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Maribel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Phillips
-
Publication number: 20140302061Abstract: The present invention relates to biomarker responsive to treatment with a TSLP antagonist.Type: ApplicationFiled: October 31, 2012Publication date: October 9, 2014Inventors: Maribel Beaumont, Jeanine D. Mattson, Jennifer R. Louten, Terrill K. McClanahan, Rene de Waal Malefyt
-
Publication number: 20140206563Abstract: A group of polypeptides that are modulated in a psoriatic sample as compared to a normal sample is provided. These polypeptides can be used as biomarkers for diagnosis and monitoring treatment of psoriasis.Type: ApplicationFiled: January 21, 2014Publication date: July 24, 2014Applicant: MERCK SHARP & DOHME CORP.Inventor: Maribel Beaumont
-
Publication number: 20130280820Abstract: A group of polypeptides that are modulated in a psoriatic sample as compared to a normal sample is provided. These polypeptides can be used as biomarkers for diagnosis and monitoring treatment of psoriasis.Type: ApplicationFiled: December 14, 2006Publication date: October 24, 2013Applicant: SCHERING CORPORATIONInventor: MARIBEL BEAUMONT
